Advisory Committee on Immunization Practices (ACIP); Correction, 16370-16371 [2021-06368]
Download as PDF
<![CDATA[
16370
Federal Register / Vol. 86, No. 58 / Monday, March 29, 2021 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Prevention and the Agency for Toxic
Substances and Disease Registry.
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Notice of Closed Meeting
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463.
Name of Committee: Safety and
Occupational Health Study Section
(SOHSS), National Institute for
Occupational Safety and Health
(NIOSH).
Date: June 15–16, 2021.
Time: 11:00 a.m.–5:00 p.m., EDT.
Place: Teleconference.
Agenda: The meeting will convene to
address matters related to the conduct of
Study Section business and for the
study section to consider safety and
occupational health-related grant
applications.
For Further Information Contact:
Michael Goldcamp, Ph.D., Scientific
Review Officer, NIOSH, CDC, 1095
Willowdale Road, Morgantown, WV
26506, Telephone (304) 285–5951;
MGoldcamp@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)RFA–OH–20–002, Commercial Fishing
Occupational Safety Research
Cooperative Agreement; and RFA–OH–
20–003, Commercial Fishing
Occupational Safety Training Project
Grants.
Date: May 26, 2021.
Time: 1:00 p.m.–4:00 p.m., EDT.
Place: Video-Assisted Meeting.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Marilyn Ridenour B.S.N., M.B.A.,
M.P.H., C.P.H., C.I.C., CAPT, USPHS,
Scientific Review Official, Office of
Extramural Programs, National Institute
for Occupational Safety and Health,
CDC, 1095 Willowdale Road,
Morgantown, West Virginia 26505,
Telephone (304) 285–5879; MRidenour@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–06369 Filed 3–26–21; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
17:20 Mar 26, 2021
Jkt 253001
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
[FR Doc. 2021–06371 Filed 3–26–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2021–0025]
Advisory Committee on Immunization
Practices (ACIP); Correction
Notice is hereby given of a change in
the meeting of the Advisory Committee
on Immunization Practices (ACIP); May
5, 2021, from 11 a.m. to 5 p.m., EDT
(times subject to change) in the original
FRN.
The virtual meeting was published in
the Federal Register on March 15, 2021,
Volume 86, Number 48, pages 14328–
14329.
The virtual meeting is being corrected
to update the CDC docket number in the
ADDRESSES section of the notice and
should read as follows:
This meeting is open to the public.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2021–
0025 by any of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS H24–8, Atlanta, GA 30329–4027,
Attn: May ACIP Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
Written public comments submitted
72 hours prior to the ACIP meeting will
be provided to ACIP members before the
meeting.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS–H24–8, Atlanta, GA 30329–
4027, Telephone: (404) 639–8367;
Email: ACIP@cdc.gov.
E:\FR\FM\29MRN1.SGM
29MRN1
Federal Register / Vol. 86, No. 58 / Monday, March 29, 2021 / Notices
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–06368 Filed 3–26–21; 8:45 am]
[FR Doc. 2021–06370 Filed 3–26–21; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Medicare & Medicaid
Services
Notice of Closed Meeting
[CMS–3408–N]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA OH–21–007, Continuation and
Expansion of the National
Mesothelioma Virtual Bank for
Translational Research.
Date: May 11, 2021.
Time: 1:00 p.m.–3:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Laurel Garrison, M.P.H., Scientific
Review Official, National Institute for
Occupational Safety and Health, CDC,
5555 Ridge Avenue, Cincinnati, Ohio
45213, Telephone (513) 533–8324;
LGarrison@cdc.gov.
CLIA Program; Announcement of the
Re-Approval of the College of
American Pathologists (CAP) as an
Accreditation Organization Under the
Clinical Laboratory Improvement
Amendments of 1988
VerDate Sep<11>2014
17:20 Mar 26, 2021
Jkt 253001
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This notice announces the
application of the College of American
Pathologists (CAP) for approval as an
accreditation organization for clinical
laboratories under the Clinical
Laboratory Improvement Amendments
of 1988 (CLIA) program. We have
determined that the CAP meets or
exceeds the applicable CLIA
requirements. In this notice, we
announce the approval and grant CAP
deeming authority for a period of 6
years.
DATES: This notice is effective from
March 27, 2021 until March 26, 2027.
FOR FURTHER INFORMATION CONTACT:
Cindy Flacks, 410–786–6520.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background and Legislative
Authority
On October 31, 1988, the Congress
enacted the Clinical Laboratory
Improvement Amendments of 1988
(CLIA) (Pub. L. 100–578). CLIA
amended section 353 of the Public
Health Service Act. We issued a final
rule implementing the accreditation
provisions of CLIA on July 31, 1992 (57
FR 33992). Under those provisions, we
may grant deeming authority to an
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
16371
accreditation organization if its
requirements for laboratories accredited
under its program are equal to or more
stringent than the applicable CLIA
program requirements in 42 CFR part
493 (Laboratory Requirements). Subpart
E of part 493 (Accreditation by a Private,
Nonprofit Accreditation Organization or
Exemption Under an Approved State
Laboratory Program) specifies the
requirements an accreditation
organization must meet to be approved
by CMS as an accreditation organization
under CLIA.
II. Notice of Approval of CAP as an
Accreditation Organization
In this notice, we approve the College
of American Pathologists (CAP) as an
organization that may accredit
laboratories for purposes of establishing
their compliance with CLIA
requirements in all specialties and
subspecialties. We have examined the
initial CAP application and all
subsequent submissions to determine its
accreditation program’s equivalency
with the requirements for approval of an
accreditation organization under
subpart E of part 493. We have
determined that the CAP meets or
exceeds the applicable CLIA
requirements. We have also determined
that the CAP will ensure that its
accredited laboratories will meet or
exceed the applicable requirements in
subparts H, I, J, K, M, Q, and the
applicable sections of R. Therefore, we
grant the CAP approval as an
accreditation organization under
subpart E of part 493, for the period
stated in the DATES section of this notice
for all specialties and subspecialties
under CLIA. As a result of this
determination, any laboratory that is
accredited by the CAP during the time
period stated in the DATES section of this
notice will be deemed to meet the CLIA
requirements for the listed specialties
and subspecialties, and therefore, will
generally not be subject to routine
inspections by a state survey agency to
determine its compliance with CLIA
requirements. The accredited laboratory,
however, is subject to validation and
complaint investigation surveys
performed by CMS, or its agent(s).
III. Evaluation of the CAP Request for
Approval as an Accreditation
Organization Under CLIA
The following describes the process
used to determine that the CAP
accreditation program meets the
necessary requirements to be approved
by CMS and that, as such, we may
approve the CAP as an accreditation
program with deeming authority under
the CLIA program. The CAP formally
E:\FR\FM\29MRN1.SGM
29MRN1
]]>Agencies
[Federal Register Volume 86, Number 58 (Monday, March 29, 2021)]
[Notices]
[Pages 16370-16371]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06368]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2021-0025]
Advisory Committee on Immunization Practices (ACIP); Correction
Notice is hereby given of a change in the meeting of the Advisory
Committee on Immunization Practices (ACIP); May 5, 2021, from 11 a.m.
to 5 p.m., EDT (times subject to change) in the original FRN.
The virtual meeting was published in the Federal Register on March
15, 2021, Volume 86, Number 48, pages 14328-14329.
The virtual meeting is being corrected to update the CDC docket
number in the ADDRESSES section of the notice and should read as
follows:
This meeting is open to the public.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2021-
0025 by any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS H24-8, Atlanta, GA 30329-4027, Attn: May ACIP
Meeting.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
Written public comments submitted 72 hours prior to the ACIP
meeting will be provided to ACIP members before the meeting.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road NE, MS-H24-8, Atlanta, GA 30329-4027, Telephone: (404) 639-8367;
Email: [email protected].
[[Page 16371]]
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-06368 Filed 3-26-21; 8:45 am]
BILLING CODE 4163-18-P
